. 2022 Jun 24;128(17):3233–3242. doi: 10.1002/cncr.34341

TABLE 2.

Unadjusted Health‐Related Quality of Life Scale Means by Patient Characteristics at Baseline, n = 1373

Characteristic	FACT‐C TOI	SF‐36 Vitality	FACT‐NTX13	FACT‐NTX4	NSABP SCL‐17
Age	r = 0.17, p < .001	r = 0.09, p = .001	r = 0.02, p = .503	r = −0.04, p = .230	r = −0.14, p < .001
Sex
Male (n = 939)	65.3^a	54.0^a	2.9^a	0.63^a	7.6^a
Female (n = 434)	65.1^a	51.6^b	2.8^a	0.71^a	8.0^a
Test	t(1365) = 0.26, p = .796	t(1367) = 3.98, p < .001	t(598) = 0.54, p = .589	t(572) = −0.67, p = .505	t(758) = −0.91, p = .364
Race/ethnicity
Hispanic (n = 85)	59.3^bc	53.1^a	4.2^ab	1.3^a	11.2^a
Non‐Hispanic Black (n = 79)	57.4^c	50.7^a	4.5^a	1.5^a	10.8^a
Non‐Hispanic White (n = 1355)	66.3^a	53.4^a	2.6^b	0.5^b	7.3^b
Non‐Hispanic Other/unknown (n = 89)	61.7^b	52.9^a	4.4^a	1.2^a	8.8^b
Test	F(3,1363) = 18.35, p < .001	F(3,1365) = 1.39, p = .246	F(3,1085) = 6.00, p = .001	F(3,1086) = 9.90, p ≤ .001	F(3,1364) = 11.22, p ≤ .001
Body mass index
<18.5 underweight (n = 17)	59.7^b	45.8^b	5.1^a	1.7^a	12.0^a
18.5–<25.0 normal (n = 358)	62.7^ab	52.2^a	2.5^b	0.6^b	8.4^b
25.0–<30.0 overweight (n = 499)	66.7^a	54.4^a	2.5^b	0.5^b	7.1^b
≥30.0 obese (n = 499)	65.9^a	53.1^a	3.5^ab	0.9^b	7.7^b
Test	F(3,1363) = 8.56, p < .001	F(3,1365) = 5.97, p < .001	F(3,1085) = 4.52, p = .004	F(3,1086) = 4.54, p = .004	F(3,1364) = 4.04, p = .007
Clinical stage
II (n = 815)	66.1^a	53.5^a	2.9^a	0.6^a	7.2^b
III (n = 557)	64.0^b	52.8^a	3.0^a	0.7^a	8.5^a
Test	t(1364) = 2.92, p = .004	t(1366) = 1.34, p = .179	t(1086) = −0.36, p = .721	t(798) = −0.82, p = .411	t(1076) = −3.26, p = .001
Karnofsky Performance Status (KPS)^a
Fully active (90–100; n = 1162)	66.7^a	54.2^a	2.6^b	0.6^b	7.1^b
Restricted/ambulatory (50–80; n = 211)	57.4^b	47.8^b	4.6^a	1.1^a	10.9^a
Test	t(261) = 8.64, p < .001	t(272) = 7.64, p < .001	t(200) = −4.00, p < .001	t(200) = −2.90, p = .004	t(247) = −5.39, p < .001
Intent to save sphincter
No (n = 357)	63.5^b	52.7^a	3.1^a	0.7^a	8.2^a
Yes (n = 1016)	65.9^a	53.4^a	2.8^a	0.7^a	7.6^a
Test	t(1365) = −3.07, p = .002	t(1367) = −1.15, p = .249	t(1087) = 0.70, p = .482	t(1088) = 0.17, p = .862	t(579) = 1.27, p = .205
Treatment
5‐FU (n = 394)	65.8^a	53.8^ab	3.0^ab	0.7^a	7.9^a
5‐FU + OXA (n = 286)	64.4^a	53.2^ab	2.8^ab	0.7^a	7.7^a
CAPE (n = 407)	65.0^a	52.1^b	3.3^a	0.7^a	8.0^a
CAPE+OXA (n = 286)	65.8^a	54.1^a	2.4^b	0.5^a	7.0^a
Test	F(3,1363) = 0.84, p = .473	F(3,1365) = 2.61, p = .050	F(3,1085) = 1.82, p = .141	F(3,1086) = 1.05, p = .371	F(3,1364) = 1.23, p = .298

Note: Student t test and analysis of variance with overall F and Duncan multiple range test used. FACT‐C‐TOI (0 − 84: higher score = better health‐related quality of life), SF‐36 Vitality T‐score (higher score = more vitality), FACT‐NTX13 (0–52: higher score = greater toxicity), FACT‐NTX4 sensory (0–16: higher score = greater toxicity), NSABP SCL‐17 (0–100: higher score = greater symptom bother).

Abbreviations: 5‐FU, 5‐fluorouracil; CAPE, capecitabine; NSABP SCL‐17, National Surgical Adjuvant Breast and Bowel Project Symptom Checklist; NTX, neurotoxicity; OXA, oxaliplatin; SF‐36, Short‐Form 36‐item Survey; TOI, Trial Outcome Index.

^{^a}

(KPS 90–100) Fully active, able to carry on all predisease performance without restriction; (KPS 70–80) restricted in physically strenuous activity but ambulatory; (KPS 50–60) ambulatory and capable of all self‐care but unable to perform any work activities.

^{^b}

Means sharing the same superscript letter (a, b, c) for a variable within a column do not differ significantly using Hochberg multiple comparison adjustment, p < .05.